Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report

被引：33
|
作者：
Oh, WK [1 ]
George, DJ
Kaufman, DS
Moss, K
Smith, MR
Richie, JP
Kantoff, PW
机构：
[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Adult Oncol, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Dept Adult Oncol, Boston, MA 02114 USA
[3] Brigham & Womens Hosp, Div Urol Surg, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Div Urol Surg, Boston, MA 02115 USA
来源：
SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 04期
关键词：
D O I：
10.1016/S0093-7754(01)90153-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：40 / 44
页数：5
相关论文
共 50 条
  • [1] Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
    Febbo, PG
    Richie, JP
    George, DJ
    Loda, M
    Manola, J
    Shankar, S
    Barnes, AS
    Tempany, C
    Catalona, W
    Kantoff, PW
    Oh, WK
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (14) : 5233 - 5240
  • [2] Neoadjuvant docetaxel and estramustine followed by radical prostatectomy or radiation therapy for patients with high-risk prostate cancer
    Stefaniak, H
    Wallen, E
    Baggstrom, M
    Godley, P
    Rosenman, J
    Goyal, L
    Whang, Y
    Pruthi, RS
    [J]. JOURNAL OF UROLOGY, 2005, 173 (04): : 190 - 190
  • [3] A phase II trial of neoadjuvant docetaxel and estramustine followed by radical prostatectomy or radiation therapy for patients with high-risk prostate cancer
    Goyal, L. K.
    Ramsey, S. N.
    Godley, P.
    Pruthi, R.
    Wallen, E.
    Whang, Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S362 - S362
  • [4] Phase II Trial of Neoadjuvant Docetaxel and Gefitinib Followed by Radical Prostatectomy in Patients With High-Risk, Locally Advanced Prostate Cancer
    Vulky, Jacqueline
    Porter, Christopher
    Isacson, Christina
    Vaughan, Matthew
    Klowski, Paul
    Picozzi, Vincent
    Corman, John
    [J]. CANCER, 2009, 115 (04) : 784 - 791
  • [5] Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP)
    Sonpavde, G.
    Frolov, A.
    Macdonell, V.
    Hayes, T. G.
    Mims, M. P.
    Ayala, G. E.
    Wheeler, T. M.
    Thompson, T. C.
    Ittman, M. M.
    Kadmon, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Garzotto, M
    Myrthue, A
    Higano, CS
    Beer, TM
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) : 254 - 259
  • [7] Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy
    Eugene J. Pietzak
    James A. Eastham
    [J]. Current Urology Reports, 2016, 17
  • [8] Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy
    Pietzak, Eugene J.
    Eastham, James A.
    [J]. CURRENT UROLOGY REPORTS, 2016, 17 (05)
  • [9] Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
    Vuky, Jacqueline
    Corman, John M.
    Porter, Christopher
    Olgac, Semra
    Auerbach, Evan
    Dahl, Kathryn
    [J]. ONCOLOGIST, 2013, 18 (06): : 687 - 688
  • [10] High-risk localized prostate cancer: role of radical prostatectomy
    Grubb, Robert L.
    Kibel, Adam S.
    [J]. CURRENT OPINION IN UROLOGY, 2010, 20 (03) : 204 - 210
12345